Weak Trigger
now
Receives formal recommendation for conditional marketing authorization from EMA's CHMP for gene-editing therapy 'Casgevy' targeting sickle cell disease.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |